Such observations further suggest that TTP may be involved in the development of radioresistance in HNSCC and that it could constitute a potential biomarker for predicting the efficacy of CD47 antibody-based treatment in recurrent HNSCC following radiotherapy [78]. The gene discussed is ZFP36; the disease is head and neck squamous cell carcinoma.